Clin2
NCT07204418Possibly a fitRecruiting

Study of KarXT effects based on CYP2D6 metabolism types

Healthy Volunteers

Treatments studied

This study tests how the drug KarXT is processed in the body based on your CYP2D6 metabolism type. It helps researchers understand if different metabolizer types affect how the drug works and is cleared.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
56 people
Ages
18 years to 65 years
Study type
Interventional

Who can take part

  • You must be a healthy adult, male or female
  • You must be a known CYP2D6 normal, extensive, intermediate, poor, or ultrarapid metabolizer
  • Your body mass index (BMI) must be between 18.0 and 32.0 kg/m2
  • You have no current organ dysfunction or other clinically significant health issues

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07063342Recruiting· Phase 1
Study of new drug versions in healthy adults

This study is testing new versions of a drug (called KarX and KarT) in healthy adults to see how the body handles them. Researchers will also look at how food affects the drug when taken multiple times.

Nottingham, Nottinghamshire
NCT07681076Not yet recruiting· Phase 4
KarXT safety study with anti-nausea meds in healthy volunteers

This trial checks if adding anti-nausea drugs to a new medication (KarXT) is safe for healthy people. It involves a 3-week stay in a research center so doctors can monitor you closely.

NCT07061288Recruiting· Phase 1
Testing a new injectable medicine for schizophrenia

This trial tests a new injectable form of KarXT for schizophrenia. It aims to see if the medicine is safe, tolerable, and how it works in the body.

Los Alamitos, California
NCT07288567Recruiting· Phase 3
KarXT for teens with schizophrenia

This trial tests if a new medicine, KarXT, can safely and effectively treat schizophrenia in adolescents. It may help teenagers who have active symptoms like hallucinations or disorganized thinking.

Anaheim, California
NCT07101094Recruiting
Study on satisfaction with a new schizophrenia treatment

This study tracks how satisfied people with schizophrenia are with a new combination medicine called xanomeline and trospium chloride (XT). It aims to understand real-world experiences and benefits of this treatment.

Costa Mesa, California
NCT06976216Recruiting· Phase 3
Study of KarXT plus KarX-EC for Alzheimer's cognitive symptoms

This trial tests a new combination treatment (KarXT plus KarX-EC) to see if it can help with thinking and memory problems caused by Alzheimer's disease. It is for people with mild to moderate Alzheimer's who have a caregiver available.

Long Beach, California

Hear when a new Healthy Volunteers trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.